PDF file: EURASNET Annual Report 2008

More documents

Recommendations

Info

TABLE OF CONTENTSA. PERIODIC ACTIVITY REPORT1. Publishable Executive Summary 42. Overview of work package activities at month 36 73. Project objectives and major achievements during the reporting period 174. Milestones and Performance Indicators4.1 Table of Milestones 184.2 Table of Performance Indicators 185. Work package reports5.1 Work packages 1-21 245.2 Consortium Management (WP22) 916. Deliverables for JPA month 25-42 937. Plan for using and disseminating the knowledge (PUDK) 108B. PERIODIC MANAGEMENT REPORT8. Tabular overview of all resources employed on the project 1209. Tabular overview of major cost items 12110. Justification of major cost items and resources10.1 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V. 12810.2 Centre de Regulació Genòmica 13310.3 Friedrich-Alexander-Universität Erlangen-Nürnberg 13510.4 Uppsala University 13710.5 European Molecular Biology Laboratory 13910.6 Tel Aviv University 14210.7 International Centre for Genetic Engineering and Biotechnology 14310.8 Medical University Vienna 14610.9 The University of Edinburgh 14810.10 Consiglio Nazionale delle Ricerche 15010.11 Justus Liebig Universität Giessen 15410.12 Centre National de Recherche Scientifique 1552
Page 4 and 5: 10.13 University of Berne 16310.14
Page 6 and 7: Prof. Andrea Barta(9) The Universit
Page 8 and 9: 2 OVERVIEW OF WORK PACKAGE ACTIVITI
Page 10 and 11: predictions from an array experimen
Page 12 and 13: WP12 Mis-splicing and diseaseGroup
Page 14 and 15: 1) The transfer of splicing factor
Page 16 and 17: two groups (SCRI, Dundee, UK; AMU,
Page 18 and 19: 3 PROJECT OBJECTIVES AND MAJOR ACHI
Page 20 and 21: eports of all EURASNET financed eve
Page 22 and 23: CAREER DEVELOPMENT• Number of peo
Page 24 and 25: Major decisions executed in swift t
Page 26 and 27: developing a team structure for gat
Page 28 and 29: Work Package 2 Sharing Resources, T
Page 30 and 31: Work Package 5 Ensuring DurabilityL
Page 32 and 33: fragment matching and a prototype v
Page 34 and 35: Work Package 7 Molecular Characteri
Page 36 and 37: -Characterisation of regulatory com
Page 38 and 39: In order to develop GFP based metho
Page 40 and 41: the stress response (Caceres, month
Page 42 and 43: sequencing. Samples are almost read
Page 44 and 45: Work Package 9 Complexity of Splice
Page 46 and 47: through a synthetic interaction scr
Page 48 and 49: phosphor-peptide specific antibodie
Page 50 and 51: spliceosome. They have now focused
Page 52 and 53:
Work Package 11 Function of Splicin
Page 54 and 55:
Work Package 12 Mis-splicing and Di
Page 56 and 57:
Work Package 13 Co-transcriptional
Page 58 and 59:
Work Package 14 Chemical Biology an
Page 60 and 61:
Selected molecules that correct the
Page 62 and 63:
Work Package 15 Development of Enab
Page 64 and 65:
Work Package 16 Conferences and mee
Page 68 and 69:
Work Package 18 Career DevelopmentL
Page 70 and 71:
Work Package 19 Public Understandin
Page 72 and 73:
PUS activitiesMany of the EURASNET
Page 74 and 75:
Work Package 20 SMEs and Technology
Page 76 and 77:
Work Package 21 Reachout to the Bro
Page 78 and 79:
Broader outreach to the wider RNA c
Page 80 and 81:
EURASNET interactions 2008Andrea Ba
Page 82 and 83:
Author Title Publication EURASNET P
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Ellis,J.D., Lleres,D., Denegri,M.,L
Page 92 and 93:
5.2 Consortium Management (Work pac
Page 94:
6 DELIVERABLES FOR JPA (MONTH 25-42
Page 97 and 98:
258 Prepare Annual Report for 2008p
Page 99 and 100:
automated methods to update thepred
Page 101 and 102:
system, Bindereif incollaboration w
Page 103 and 104:
(e.g. A, B, or C) on thetranscripti
Page 105 and 106:
trans-acting factors of particulari
Page 107 and 108:
will further improve their U7-based
Page 109 and 110:
7 UPDATED PLAN FOR USING AND DISSEM
Page 111 and 112:
Auweter S.D., Allain F.H.-T.Author
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Lorković ZJ, Barta A.Author Title
Page 121 and 122:
8 TABULAR OVERVIEW OF ALL RESOURCES
Page 123 and 124:
travel 0 300,06 774,06overhead 6.81
Page 125 and 126:
training 0 0equipment 0 0travel 0 2
Page 127 and 128:
consumables 14.093,34 1.617,49 8153
Page 129 and 130:
10 JUSTIFICATION OF MAJOR COST ITEM
Page 131 and 132:
PersonnelScientific Network Manager
Page 133 and 134:
Participant 1C - Henning Urlauba) W
Page 135 and 136:
• WP21Lectured on RNA biology and
Page 137 and 138:
Bennewitz Elke 1.536,89Preller Rosa
Page 139 and 140:
Major cost items• ResearchPersonn
Page 141 and 142:
The second is hands on training for
Page 143 and 144:
Participant 6 - Gil Asta) Work perf
Page 145 and 146:
these other hnRNP factors is of fun
Page 147 and 148:
Participant 8 - Andrea Bartaa) Work
Page 149 and 150:
Participant 9 - Jean Beggsa) Work p
Page 151 and 152:
Participant 10A - Giuseppe Biamonti
Page 153 and 154:
Participant 10B - Glauco Tocchini-V
Page 155 and 156:
Participant 11 - Albrecht Bindereif
Page 157 and 158:
Presented EURASNET-related material
Page 159 and 160:
) Major cost items with justificati
Page 161 and 162:
effects of HeLa cell’s growth con
Page 163 and 164:
ConsumablesOligonucleotidesChemical
Page 165 and 166:
c) Main activities planned for the
Page 167 and 168:
) Major cost items with justificati
Page 169 and 170:
Participant 16 - Maria Carmo-Fonsec
Page 171 and 172:
Participant 17 - Ian C. Eperona) Wo
Page 173 and 174:
Participant 18 - Artur Jarmolowskia
Page 175 and 176:
Participant 19 - Jørgen Kjemsa) Wo
Page 177 and 178:
Participant 20 - Alberto Kornblihtt
Page 179 and 180:
• ResearchPersonnelIvona Bagdiul
Page 181 and 182:
The stable cell lines have been tes
Page 183 and 184:
Participant 24 - Hermona Soreqa) Wo
Page 185 and 186:
Participant 25 - James SteveninWP 7
Page 187 and 188:
Participant 27 - Davide Gabellinia)
Page 189 and 190:
Participant 28 - Mihaela Zavolana)
Page 191 and 192:
Participant 30 - Janusz Bujnickia)
Page 193 and 194:
Participant 31 - Eduardo Eyrasa) Wo
Page 195 and 196:
Participant 32 - Diana Barallea) Wo
Page 197 and 198:
MPG1aMPG1bMPG1cCRGUERLNUUEMBL5aEMBL
Page 199 and 200:
Type of Instrument NoE Project Titl
Page 201 and 202:
Direct eligible costs 39.626,75 0,0
Page 203 and 204:
Direct eligible costs 0,00 0,00 0,0
Page 205 and 206:
Report on the Distribution of the C
Page 207 and 208:
14 SUMMARY EXPLANATION OF THE IMPAC
Page 209 and 210:
The website is an important tool fo
Page 211 and 212:
By February 2009 ASTD and Integr8 w
Page 213 and 214:
will prove necessary to focus the s
Page 215 and 216:
Work Package 10: Post-translational
Page 217 and 218:
splicing (c-fos) increases when elo
Page 219 and 220:
TABLE: Relationship of transcriptio
Page 221 and 222:
HIV-1 and other retroviruses inhibi
Page 223 and 224:
experiments. We will also attempt t
Page 225 and 226:
[This page deliberately left empty.
Page 227 and 228:
18. CAREER DEVELOPMENT (Kjems)caree
Page 229 and 230:
Interactions among EURASNET partici
Page 231 and 232:
15.5 DELIVERABLES LIST (MONTHS 37-5
Page 233 and 234:
163 The Eyras group incollaboration
Page 235 and 236:
202 Srebrow will investigate therol
Page 237 and 238:
224 Schümperli's group willfurther
Page 239 and 240:
267 GROUP 16 (CARMO- 12 F. Baralle
Page 241 and 242:
288 Groups 12a (C Branlant) willcon
Page 243 and 244:
306 Establishing interaction mapsam
Page 245 and 246:
320 Tazi has identified theDrosophi
Page 247 and 248:
330 GROUP 11 (BINDEREIF)will contin
Page 249 and 250:
338 Role of the U1 snRNP in“rever
Page 251 and 252:
352 Arrangement of a 1-daycareer de
Page 253 and 254:
15.6 JOINT PROGRAM OF ACTIVITIES (M
Page 255 and 256:
4. The Alternative Splicing and Tra
Page 257 and 258:
6. In silico approaches to alternat
Page 259 and 260:
287 Group 7 (F Baralle) will contin
Page 261 and 262:
Deliverables176, 180, 184, 185 all
Page 263 and 264:
10. Post-translational Modification
Page 265 and 266:
11. Function of Splicing Factor Iso
Page 267 and 268:
properties of the human TDP-43 prot
Page 269 and 270:
339 Establishment of “model genes
Page 271 and 272:
223 Development of clinically usefu
Page 273 and 274:
16. Conferences and meetingsWorkpac
Page 275 and 276:
17. Staff Exchange and TrainingWork
Page 277 and 278:
19. Public Understanding of RNA Bio
Page 279 and 280:
Deliverables249 Screen at least 10,
Page 281 and 282:
22. ManagementWorkpackage descripti
Page 283 and 284:
15.8 PMs FOR THE 4th 18 MONTH PERIO
Page 285 and 286:
15.9 Efforts for the full duration
Page 287 and 288:
16 Project management level descrip
Page 289 and 290:
630,000 € 180,000 € 210,000 €
Page 291 and 292:
290Fig. 7 Budget
Page 293 and 294:
Joint Programme of ActivitiesINTEGR
Page 295 and 296:
The Meeting and conference programm
show all

PDF file: EURASNET Annual Report 2008

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?